Copyright
©The Author(s) 2020.
World J Gastroenterol. Jun 7, 2020; 26(21): 2864-2876
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2864
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2864
Table 2 Liver stiffness measurements of all patients at baseline and sustained virologic response 12
| Total baseline | Changes in the fibrosis grade at SVR12 | |||
| F0-1 (%) | F2 (%) | F3 (%) | F4 (%) | |
| F0-1 29 (36.3%) | 23 (79.3) | 5 (17.2) | 1 (3.4) | 0 (0.0) |
| F2 20 (25%) | 10 (50) | 10 (50) | 0 (0.0) | 0 (10) |
| F3 5 (6.3%) | 1 (20) | 2 (40) | 1 (20) | 1 (20) |
| F4 26 (32.5%) | 1 (3.8) | 6 (23.1) | 4 (15.4) | 15 (57.7) |
| Total SVR12 | 35 (43.7) | 23 (28.7) | 6 (7.5) | 16 (20) |
- Citation: Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876
- URL: https://www.wjgnet.com/1007-9327/full/v26/i21/2864.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i21.2864